about
A clinical trial of neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma.The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Treatment Outcomes and Prognostic Factors in Adult Astrocytoma: In North East of Iran.A comprehensive approach in high-grade glioma management: position statement from the Neuro-Oncology Scientific Club (NOSC), Shiraz, Iran.The Comparison of the Advantages of Neoadjuvant Chemoradiotherapy versus Postoperative Chemoradiotherapy: Outcomes in Esophageal Cancer Patients.The cross-regulation between SOX15 and Wnt signaling pathway.The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.New methods for optical distance indicator and gantry angle quality control tests in medical linear accelerators: image processing by using a 3D phantom.Pituitary Glioblastoma: A Case Report.Pattern and distribution of bone metastases in common malignant tumors.Pulmonary metastasectomy and repeat metastasectomy for soft-tissue sarcoma.A comparison of the doses received by normal cranial tissues during different simple model conventional radiotherapeutic approaches to pituitary tumours.Intelligent modelling of oesophageal cancer treatment and its use to determine the dose of chemotherapy drug.A genetic polymorphism in the CYP1B1 gene in patients with squamous cell carcinoma of the esophagus: an Iranian Mashhad cohort study recruited over 10 years.Expression of p63 and CD44 in oral squamous cell carcinoma and correlation with clinicopathological parameters.Primary duodenal malignant melanoma: A case report.Evaluation of serum levels of oxidized and reduced glutathione and total antioxidant capacity in patients with head and neck squamous cell carcinomaA genetic variant in CDKN2A/2B locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma
P50
Q36298303-57C039D2-810C-4AAC-A248-04C9A72454AAQ36299167-E747BB84-64C4-498B-B4AB-37377B99CC56Q37397997-45AFF159-AEB4-4FC8-BEAF-C876C31D568EQ37675804-CE108459-E691-4B42-A160-DFCC467BC5C1Q39062951-ADB3C584-22BD-4DA4-8AE2-144006391FDEQ39090367-6FEB6D50-950A-406E-B98E-1EF848E2ED52Q39097267-DD431904-F8B6-4E76-895A-E642715011CDQ39163561-653A80A1-84D0-4F2E-AE9B-E7F0F0221902Q39540517-CB17DD65-347C-4F00-90D1-86A7615FAD92Q43219604-7F3F89C4-7FCB-434A-A5C7-1543746ADCD1Q43988058-357A78F8-BEE9-4403-90E9-78A388F9C790Q45923790-3FF53DD4-F59D-4D68-9B77-47999C38637EQ51315727-F929F499-922C-4240-BC03-77AEE4B0D283Q51358374-24B5EF31-E2D4-4CEE-84E9-447F370B27FCQ52720744-AC19CC4A-664E-4AE3-A400-0850B4A034D2Q53199988-5E325417-E34B-43BA-8243-3652941BCBD8Q64884950-8102E22D-88FA-4EB5-BDEB-AA7CD44F3922Q87999860-6C5D6B9F-3E09-4D8A-B39A-F89E9F0AD461Q91611905-180949A8-FFD0-4A43-8C91-7E51EED17525
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
K Anvari
@en
K Anvari
@nl
type
label
K Anvari
@en
K Anvari
@nl
prefLabel
K Anvari
@en
K Anvari
@nl
P31
P496
0000-0002-1080-1907